BLASUBCUTANEOUSSOLUTION
Approved
Nov 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
XULTOPHY 100/3.6 (insulin degludec and liraglutide) by Novo Nordisk is glucagon-like peptide-1 (glp-1) agonists [moa]. Approved for insulin analog [epc]. First approved in 2016.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XULTOPHY 100/3.6 is a fixed-dose combination of insulin degludec (a basal insulin analog) and liraglutide (a GLP-1 receptor agonist) administered via subcutaneous injection. It is indicated for type 2 diabetes mellitus in patients requiring both basal insulin and GLP-1 agonist therapy. The combination provides dual glycemic control through complementary mechanisms: sustained basal insulin coverage and incretin-mediated glucose lowering with weight benefit.
Peak
Product is at peak commercial stage with established market presence; roles focus on market penetration, payer strategy, and defending against competitive erosion.
Mechanism of Action
Glucagon-like Peptide-1 (GLP-1) Agonists
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
Started Sep 2017
24 enrolled
DiabetesDiabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.
Started Nov 2015
819 enrolled
DiabetesDiabetes Mellitus, Type 2
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
Started May 2011
1,663 enrolled
DiabetesDiabetes Mellitus, Type 2
Worked on XULTOPHY 100/3.6 at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.